RE:RE:Very encouraging, but approval will take timeAnother thing I learned today is that they do a biopsy on all patients before starting them on the drug. Maybe I missed it previously, but it changes the situation they are in. It seems that the FDA is asking them to do that, but not to use it as a selection tool. The FDA is also thinking in an ADC way, not in a PDC way. They look at how it was done before with ADCs, and forget that TH1902 is a PDC. Both targeted therapies, yes, but very different.